PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults

Phase 3

Active, not recruiting

Conditions: Hemophilia A

First Posted Date: 2020-04-30

Last Posted Date: 2025-05-15

Lead Sponsor: Pfizer

Target Recruit Count: 76

Registration Number: NCT04370054

Locations: 🇺🇸
NOW Physical Therapy, Mountain View, California, United States
🇺🇸
Clinical and Translational Research Unit (CTRU), Palo Alto, California, United States
🇺🇸
Lucile Packard Childrens Hospital, Palo Alto, California, United States

and more 33 locations

Crisaborole for Chinese and Japanese Subjects (≥2 Years of Age) With Mild to Moderate Atopic Dermatitis

Phase 3

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Crisaborole Ointment
Drug: Crisaborole Placebo Vehicle

First Posted Date: 2020-04-24

Last Posted Date: 2022-06-07

Lead Sponsor: Pfizer

Target Recruit Count: 391

Registration Number: NCT04360187

Locations: 🇯🇵
Iryouhoujinshadan Yamayurikai Tsujino. Kodomo Clinic, Kobe-City, Hyōgo, Japan
🇯🇵
Miyata Dermatology Clinic, Matsudo City, Chiba, Japan
🇯🇵
Chitose dermatology and plastic surgery clinic, Chitose Shi, Hokkaido, Japan

and more 36 locations

Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer

Phase 4

Completed

Conditions: Carcinoma
Non-Small-Cell Lung

Interventions: Drug: Lorlatinib

First Posted Date: 2020-04-24

Last Posted Date: 2024-11-11

Lead Sponsor: Pfizer

Target Recruit Count: 71

Registration Number: NCT04362072

Locations: 🇮🇹
Policlinico "G. Rodolico", Catania, Italy
🇺🇸
UCI Medical Center/Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸
University Cancer & Blood Center, Llc, Athens, Georgia, United States

and more 38 locations

A STUDY TO EVALUATE THE EFFECT OF PF-06651600 ON PHARMACOKINETICS OF SINGLE DOSE SUMATRIPTAN IN HEALTHY PARTICIPANTS.

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Sumatriptan
Drug: PF-06651600

First Posted Date: 2020-04-21

Last Posted Date: 2020-09-03

Lead Sponsor: Pfizer

Target Recruit Count: 10

Registration Number: NCT04355845

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

A Study to Assess Efficacy and Safety of PF-06462700 in Japanese Participants With Aplastic Anemia

Phase 3

Completed

Conditions: Aplastic Anemia

Interventions: Biological: PF-06462700

First Posted Date: 2020-04-17

Last Posted Date: 2022-04-27

Lead Sponsor: Pfizer

Target Recruit Count: 3

Registration Number: NCT04350606

Locations: 🇯🇵
Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan
🇯🇵
Nagoya University Hospital, Nagoya, Aichi, Japan
🇯🇵
Keio University Hospital, Shinjuku-ku, Tokyo, Japan

Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns

Completed

Conditions: Non-Small-Cell Lung Carcinoma

Interventions: Drug: Alectinib

First Posted Date: 2020-04-17

Last Posted Date: 2023-03-27

Lead Sponsor: Pfizer

Target Recruit Count: 1

Registration Number: NCT04351334

Locations: 🇺🇸
Pfizer Inc, New York, New York, United States

Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen

Phase 2

Terminated

Conditions: COVID-19 Infection

Interventions: Drug: Placebo
Drug: Zavegepant (BHV-3500)

First Posted Date: 2020-04-15

Last Posted Date: 2024-05-02

Lead Sponsor: Pfizer

Target Recruit Count: 47

Registration Number: NCT04346615

Locations: 🇺🇸
Jefferson Torresdale Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
Georgetown University Hospital, Washington, District of Columbia, United States

and more 3 locations

Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

Phase 3

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Abrocitinib 200 mg
Combination Product: Dupilumab 300 mg

First Posted Date: 2020-04-14

Last Posted Date: 2022-07-08

Lead Sponsor: Pfizer

Target Recruit Count: 727

Registration Number: NCT04345367

Locations: 🇺🇸
One Health Research Clinic, Norcross, Georgia, United States
🇺🇸
Paddington Testing Co, Inc., Philadelphia, Pennsylvania, United States
🇵🇱
Centrum Medyczne Promed, Krakow, Poland

and more 146 locations

Observational Study To Assess The Effectiveness and Treatment Adherence Of Tofacitinib of Ulcerative Colitis In Clinical Practice In Sweden

Recruiting

Conditions: Ulcerative Colitis

Interventions: Drug: tofacitinib

First Posted Date: 2020-04-08

Last Posted Date: 2025-04-16

Lead Sponsor: Pfizer

Target Recruit Count: 120

Registration Number: NCT04338204

Locations: 🇸🇪
Medicinkliniken, Umeås Universitetssjukhus, Umeå, Sweden
🇸🇪
Specialmedicin, Akademiska Sjukhuset, Sjukhusvägen ing 40, Uppsala, Sweden
🇸🇪
Medicinmottagningen gastroenterologi, Västmanlands sjukhus, Västerås, Sweden

and more 14 locations

A Study In Adult Healthy Volunteers To Asses Once Daily (QD) Dosing With The Selected Age-Appropriate Modified Release (MR) Formulations

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: tofacitinib modified release (MR)

First Posted Date: 2020-04-08

Last Posted Date: 2020-10-29

Lead Sponsor: Pfizer

Target Recruit Count: 23

Registration Number: NCT04338711

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy